Health

In a rapidly aging society, understanding the factors that influence cognitive health in older adults is paramount. Recent research aimed at unriddling the potential connection between antibiotic use and dementia risk has yielded intriguing results. A prospective study conducted over nearly five years has found no substantial link between antibiotics and increased dementia incidence in
In recent years, the landscape of physician employment and collective action within the healthcare industry has undergone significant changes. The data emerging from the National Labor Relations Board (NLRB) provides compelling insights into the evolution of union petitions among physicians, particularly highlighting a notable surge in 2023-2024 compared to earlier years (2000-2022). This phenomenon represents
The evolving landscape of health issues in the United States presents a cluster of challenges that demand immediate attention. The recent surgery of Hall of Fame NFL receiver Randy Moss for bile duct cancer underscores the vulnerability of even the most celebrated athletes. His battle is a poignant reminder of the unforgiving nature of health
Per- and polyfluoroalkyl substances (PFAS) have become ubiquitous in modern life, often without consumer awareness. Laurel Schaider, a prominent scientist, articulates a crucial warning: when we use products containing PFAS, like dental floss, we are inadvertently exposing ourselves to hazardous substances. This situation raises significant health concerns, especially given that PFAS are linked to numerous
A growing body of research emphasizes the significant influence of dietary patterns on cognitive health, particularly among older adults. Recent findings from the Framingham Heart Study Offspring cohort indicate that diets characterized by high levels of inflammatory foods correlate with an elevated risk of developing dementia, including Alzheimer’s disease. This information highlights an urgent need
The medical community woke up to unsettling news regarding obeticholic acid, marketed as Ocaliva, a medication approved for the treatment of primary biliary cholangitis (PBC). The U.S. Food and Drug Administration (FDA) has raised alarms about serious liver injury risks associated with the drug in patients without cirrhosis. This announcement emerged from ongoing reviews and
Chronic lymphocytic leukemia (CLL) remains one of the most challenging hematological malignancies to treat, particularly in patients who have already received prior therapies, including covalent Bruton’s tyrosine kinase (BTK) inhibitors like ibrutinib. Recent findings presented at the American Society of Hematology’s annual meeting have shed light on a promising alternative, pirtobrutinib (marketed as Jaypirca), a